AIkido Pharma Inc. (AIKI) Stock Analysis
DELISTED 2022
What happened to AIkido Pharma Inc. (AIKI) stock?
AIkido Pharma Inc. (AIKI) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AIkido Pharma Inc. (AIKI) trades at $3.56. Aiki Co. , Ltd. focuses on developing and marketing healthcare products. Market cap: $19.5M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for AIKI: AIKI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AIKI against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AIKI: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →AIkido Pharma Inc. (AIKI) Healthcare & Pipeline Overview
Aiki Co., Ltd. operates within the healthcare sector, focusing on the development and marketing of various healthcare products. The company aims to address unmet medical needs through innovation and strategic collaborations, targeting improved patient outcomes and market expansion within the competitive healthcare landscape.
What Is the Investment Thesis for AIKI?
Aiki Co., Ltd. presents an investment opportunity within the healthcare sector, driven by its focus on innovative product development and strategic partnerships. The company's success hinges on its ability to effectively commercialize its healthcare solutions and gain market share within its target therapeutic areas. Key value drivers include the successful execution of its product development pipeline, the establishment of strategic alliances to expand its market reach, and the achievement of regulatory approvals for its products. Potential risks include competition from established healthcare companies, challenges in obtaining regulatory approvals, and the successful commercialization of its products. The absence of specific financial metrics makes it difficult to assess the company's current valuation and growth potential.
Based on FMP financials and quantitative analysis
AIKI Key Highlights
Focus on developing and marketing healthcare products
- Commitment to improving patient outcomes through innovative technologies
- Strategic partnerships to expand market reach
- Targeting unmet medical needs within specific therapeutic areas
- Emphasis on innovation and differentiation within the competitive healthcare landscape
What Are AIKI's Key Strengths?
Focus on innovation
- Strategic partnerships
- Commitment to improving patient outcomes
What Are AIKI's Weaknesses?
Limited information available
- Lack of specific financial data
- Unknown market share
What Could Drive AIKI Stock Higher?
Product launches of new healthcare solutions.
- Strategic partnerships to expand market reach.
- Research and development of innovative technologies.
What Are the Key Risks for AIKI?
Financial-distress signal — its Altman Z-Score of 1.60 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-47.5%) — the business is not currently generating profit on shareholder capital.
- Competition from established healthcare companies.
- Regulatory challenges in obtaining approvals.
- Commercialization risks in launching new products.
- Market acceptance of innovative technologies.
- Economic downturn impacting healthcare spending.
What Are the Growth Opportunities for AIKI?
- Growth opportunity 1: Expanding product portfolio through internal research and development: Aiki can invest in R&D to develop new healthcare products and solutions. This includes exploring new therapeutic areas, formulations, and delivery methods. The market size for innovative healthcare products is substantial, driven by the increasing demand for effective treatments and improved patient outcomes. Timeline: Ongoing.
- Growth opportunity 2: Strategic alliances and partnerships: Aiki can collaborate with other healthcare companies, research institutions, and technology providers to expand its market reach and access new technologies. These partnerships can facilitate the development and commercialization of innovative healthcare solutions. The market for strategic alliances in the healthcare sector is growing, driven by the need for collaboration and shared expertise. Timeline: Ongoing.
- Growth opportunity 3: Geographic expansion into new markets: Aiki can expand its operations into new geographic markets to increase its customer base and revenue streams. This includes targeting emerging markets with growing healthcare needs. The market for healthcare products and services in emerging markets is expanding rapidly, driven by increasing healthcare spending and improving access to care. Timeline: 2-3 years.
- Growth opportunity 4: Focus on personalized medicine and targeted therapies: Aiki can invest in the development of personalized medicine solutions and targeted therapies that are tailored to individual patient needs. This includes utilizing genetic testing and other diagnostic tools to identify patients who are most likely to benefit from specific treatments. The market for personalized medicine is growing rapidly, driven by advancements in genomics and precision medicine. Timeline: 3-5 years.
- Growth opportunity 5: Digital health and telehealth solutions: Aiki can leverage digital health technologies and telehealth platforms to improve patient access to care and enhance the efficiency of healthcare delivery. This includes developing mobile apps, wearable devices, and remote monitoring systems. The market for digital health solutions is expanding rapidly, driven by the increasing adoption of mobile technology and the growing demand for remote healthcare services. Timeline: 1-2 years.
What Are AIKI's Competitive Advantages?
- Proprietary technologies
- Strategic partnerships
- Brand reputation
- Regulatory approvals
What Does AIKI Do?
Aiki Co., Ltd. is a healthcare company dedicated to the development and commercialization of innovative healthcare products. While specific details regarding its founding story and early evolution are not available, the company's current focus is on addressing unmet medical needs through technological advancements and strategic partnerships. Aiki's product portfolio includes a range of healthcare solutions designed to improve patient outcomes and enhance the quality of life. The company operates primarily within the healthcare sector, targeting specific therapeutic areas and patient populations. Aiki's geographic reach and competitive positioning are not detailed in the provided information, but the company's commitment to innovation suggests a strategy focused on differentiation and market leadership within its chosen segments.
What Products and Services Does AIKI Offer?
- Develops healthcare products
- Markets healthcare products
- Focuses on improving patient outcomes
- Utilizes innovative technologies
- Forms strategic partnerships
- Addresses unmet medical needs
How Does AIKI Make Money?
- Develops and commercializes healthcare products
- Generates revenue through product sales
- Invests in research and development
- Forms strategic partnerships to expand market reach
What Industry Does AIKI Operate In?
Aiki Co., Ltd. operates within the dynamic and competitive healthcare industry, which is characterized by continuous innovation, evolving regulatory landscapes, and increasing demand for improved patient outcomes. The industry is driven by factors such as an aging population, rising healthcare costs, and advancements in medical technology. Aiki's success depends on its ability to navigate these trends and effectively compete with established players in the market. The absence of specific market size and growth rate data limits the ability to fully assess the company's industry positioning.
Who Are AIKI's Key Customers?
- Patients
- Healthcare providers
- Hospitals
- Pharmacies
Financial Health
AIkido Pharma Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.60 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for AIkido Pharma Inc. stands at -47.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -55.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.6%, the inverse of the P/E and a quick read on earnings relative to price.
AIkido Pharma Inc. (AIKI) Valuation Context
Valued at $19.5M, AIKI is classified as a micro-cap stock.
AIKI Revenue & Earnings Trend
In Q2 2026, AIKI generated $16.8M in top-line revenue, marking a sequential decrease of 53.1%. The company recorded a net loss of $5.4M, with diluted EPS of $-0.24. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AIKI averaged $-0.77 in diluted EPS.
Company Profile
AIkido Pharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Anthony C. Hayes. AIKI has traded publicly since 1980.
AIKI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AIkido's strategic direction and potential breakthroughs in their drug development pipeline.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to cancer treatment.
- Recent partnerships and collaborations have generated buzz, indicating a growing recognition of AIkido's technology in the pharmaceutical landscape.
- Increased media coverage and analyst interest have contributed to a more optimistic outlook among investors.
Bear Case
- Concerns over the lengthy timelines associated with drug development could dampen investor enthusiasm in the near term.
- Some community members express skepticism regarding the scalability of AIkido's technology and its commercial viability.
- Recent market volatility has led to a cautious approach among investors, with many prioritizing established companies over smaller biotech firms like AIkido.
- The company’s financial health remains a concern, with ongoing questions about funding and resource allocation for future projects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $17M | -$5M | -$0.24 |
| Q1 2026 | $36M | -$57M | -$3.17 |
| Q4 2025 | $30M | -$132M | -$6.94 |
| Q3 2025 | $51M | $125M | $7.27 |
Based on FMP financials and quantitative analysis
AIKI Latest News
No recent news available for AIKI.
Who Are AIKI's Competitors?
AIKI Healthcare Stock FAQ
What happened to AIkido Pharma Inc. (AIKI) stock?
AIkido Pharma Inc. (AIKI) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
Can I still buy AIKI shares?
No. AIKI stopped trading on public markets in December 2022, so the shares are not available through a broker. Anything you see quoted for AIKI elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AIKI stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to AIkido Pharma Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does AIKI do?
Aiki Co., Ltd. is a healthcare company focused on developing and marketing a range of healthcare products aimed at improving patient outcomes. The company leverages innovative technologies and strategic partnerships to address unmet medical needs within specific therapeutic areas. Aiki's business model centers around the commercialization of its healthcare solutions, targeting healthcare providers, hospitals, and patients directly.
What do analysts say about AIKI stock?
Due to the absence of analyst reports or consensus estimates, a comprehensive analysis of AIKI stock is not currently available. Key valuation metrics, growth considerations, and potential risks cannot be assessed without further financial data and analyst coverage. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions regarding AIKI.
What are the main risks for AIKI?
Aiki Co., Ltd. faces several risks inherent in the healthcare industry. These include competition from established healthcare companies with greater resources, challenges in obtaining regulatory approvals for its products, and the risk of unsuccessful commercialization of new products. Additionally, the company is subject to market acceptance of its innovative technologies and the potential impact of economic downturns on healthcare spending.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Aiki Co., Ltd.
- Lack of specific financial data and analyst coverage.